Skip to main content
SpringerLink
Log in

Kutane Nebenwirkungen der medikamentösen Tumortherapie

Cutaneous side effects of medical tumor therapy

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Substanzen, die zur medikamentösen Tumortherapie eingesetzt werden, können kutane Nebenwirkungen mit einem relativ typischen klinischen Bild hervorrufen. Vor allem die neuen zielgerichteten Therapien sind häufig mit spezifischen kutanen Nebenwirkungen assoziiert, wie z. B. papulopustulöse Exantheme unter EGFR-Blockern und Hauttumoren unter BRAF-Blockern. In dieser Übersicht werden das klinische Bild sowie pathogenetische und therapeutische Aspekte dieser kutanen Nebenwirkungen zusammengefasst, insbesondere des Hand-Fuß-Syndroms, des papulopustulösen Exanthems, der epithelialen Hauttumoren, der Paronychien sowie der Veränderungen von Nägeln und Haaren. Um Pausierungen oder ein vorzeitiges Absetzen der medikamentösen Tumortherapie zu vermeiden, sind die Kenntnis der spezifischen Nebenwirkungen sowie des Nebenwirkungsmanagements wichtig, insbesondere da bei einigen Substanzen ein Zusammenhang zwischen kutanen Reaktionen und dem Ansprechen der Therapie beobachtet wurde.

Abstract

Agents used in medical tumor therapies can cause peculiar cutaneous side effects. In particular the newly developed targeted therapies are associated with specific cutaneous side effects, such as a papulopustular exanthems associated with EGFR inhibitors and epithelial skin cancers associated with inhibitors of mutated BRAF. In this review the clinical pictures as well as pathogenetic and therapeutic aspects of the hand-foot-syndrome, papulopustular exanthems, epithelial skin cancers, paronychia and changes of hair and nails as side effects of medical tumor therapies are summarized. Knowledge of these side effects is important to avoid interruption or termination of the tumor therapy, in particular since some of the cutaneous reactions have been shown to correlate with the therapeutic benefit of the tumor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Meta-Analysis Group In Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537–3541

    Google Scholar 

  2. Arnault JP, Wechsler J, Escudier B et al (2009) Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 27:e59–e61

    Article  PubMed  Google Scholar 

  3. Balagula Y, Barth HK, Busam KJ et al (2010) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs [Epub ahead of print]

  4. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  PubMed  CAS  Google Scholar 

  5. Lopez V, Pinazo I, Marti N et al (2008) Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. J Eur Acad Dermatol Venereol 23:959–960

    Article  PubMed  Google Scholar 

  6. Chen M, Crowson AN, Woofter M et al (2004) Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 31:818–820

    PubMed  Google Scholar 

  7. Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy – classification and management. J Dtsch Dermatol Ges 8:652–661

    PubMed  Google Scholar 

  8. Degen A, Satzger I, Voelker B et al (2010) Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers. Dermatology 221:193–196

    Article  PubMed  CAS  Google Scholar 

  9. Eames T, Grabein B, Kroth J, Wollenberg A (2010) Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 24:958–960

    Article  PubMed  CAS  Google Scholar 

  10. Fox LP (2007) Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56:460–465

    Article  PubMed  Google Scholar 

  11. Gutzmer R, Becker JC, Enk A et al (2010) Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 9:195–203

    PubMed  Google Scholar 

  12. Gutzmer R, Werfel T, Kapp A, Elsner J (2006) Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 57:509–513

    Article  PubMed  CAS  Google Scholar 

  13. Gutzmer R, Werfel T, Mao R et al (2005) Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153:849–851

    Article  PubMed  CAS  Google Scholar 

  14. Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317–326

    Article  PubMed  Google Scholar 

  15. Joncas V, Sammour R, Krasny M et al (2008) A distinct cutaneous reaction to sorafenib and a multikinase inhibitor. Int J Dermatol 47:767–769

    Article  PubMed  Google Scholar 

  16. Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955–1961

    Article  PubMed  CAS  Google Scholar 

  17. Lee WJ, Lee JL, Chang SE et al (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161:1045–1051

    Article  PubMed  CAS  Google Scholar 

  18. Marquez CB, Smithberger EE, Bair SM et al (2009) Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control 16:66–69

    PubMed  Google Scholar 

  19. Potthoff K, Hofheinz R, Hassel JC et al (2010) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524–535

    Article  PubMed  Google Scholar 

  20. Reck M, Gutzmer R (2010) Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 33:470–479

    Article  PubMed  CAS  Google Scholar 

  21. Robert C, Arnault JP, Mateus C (2010) RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23:177–182

    Article  Google Scholar 

  22. Robert C, Mateus C, Spatz A et al (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299–305

    Article  PubMed  Google Scholar 

  23. Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491–500

    Article  PubMed  CAS  Google Scholar 

  24. Smith KJ, Haley H, Hamza S, Skelton HG (2009) Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 35:1766–1770

    Article  PubMed  CAS  Google Scholar 

  25. Strumberg D, Awada A, Hirte H et al (2006) Pooled safety analysis of BAY 43–9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42:548–556

    Article  PubMed  CAS  Google Scholar 

  26. Ulrich J, Hartmann JT, Dorr W, Ugurel S (2008) Skin toxicity of anti-cancer therapy. J Dtsch Dermatol Ges 6:959–977

    Article  PubMed  Google Scholar 

  27. Valks R, Fraga J, Porras-Luque J et al (1997) Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 133:873–878

    Article  PubMed  CAS  Google Scholar 

  28. Wolf SL, Qin R, Menon SP et al (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28:5182–5187

    Article  PubMed  CAS  Google Scholar 

  29. Wollenberg A, Moosmann N, Kroth J et al (2007) Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Hautarzt 58:615–618

    Article  PubMed  CAS  Google Scholar 

  30. Wollenberg A, Staehler M, Eames T (2010) Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib. Hautarzt 61:662–667

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: R. Gutzmer erhielt Vortragshonorare von Roche Pharma und MerckSerono. Die weiteren Autoren geben an, dass keine Interessenkonflikte bestehen.

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Allergologie und Venerologie, Hauttumorzentrum Hannover (HTZH), Medizinische Hochschule Hannover, Ricklinger Str. 5, 30449, Hannover, Deutschland

    A. Degen, M. Alter, F. Schenck, A. Kapp & R. Gutzmer

Authors
  1. A. Degen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Alter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Schenck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Gutzmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Degen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Degen, A., Alter, M., Schenck, F. et al. Kutane Nebenwirkungen der medikamentösen Tumortherapie. Hautarzt 62, 444–451 (2011). https://doi.org/10.1007/s00105-010-2042-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-2042-4

Schlüsselwörter

Keywords

Search

Navigation